Klin Farmakol Farm. 2004;18(3):144-145

Konzervativní léčba Crohnovy nemoci

Michal Konečný
II. interní klinika FN a LF UP Olomouc

Keywords: inflammatory bowel disease, Crohn disease, aggressive treatment, maintenance treatment.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Konečný M. Konzervativní léčba Crohnovy nemoci. Klin Farmakol Farm. 2004;18(3):144-145.

Léčbu Crohnovy nemoci dělíme na chirurgickou a konzervativní. Základem konzervativní terapie zůstávají preparáty kyseliny 5-aminosalicylové, kortikosteroidy, antibiotika a imunosupresiva. Rozhodující pro úspěch léčby je vhodně zvolená taktika léčby s ohledem na typ, rozsah, lokalizaci a dosavadní průběh choroby. Strategii je nutno změnit i v případě jedná-li se o útočnou léčbu, kdy podáváme až maximální dávky léků, nebo léčbu udržovací, kdy se snažíme zabránit relapsu onemocnění dlouhodobým podáváním menších dávek léčiv. Pro řadu nemocných je velkým příslibem biologická terapie, především podávání protilátek proti tumor nekrotizujícímu faktoru alfa. S dalšími látkami z této skupiny probíhají v celém světe velmi intenzivně klinické zkoušky.

CONSERVATIVE TREATMENT OF CROHN DISEASE

Treatment of Crohn disease is conservative and surgical. The core of the conservative treatment remain derivatives of 5-aminosalicylic acid, corticosteroids, antibiotics and immunosuppressives. Crucial for a successful treatment is adequately chosen treatment tactics with regards to type, extent, localisation and existing course of the disease. Strategy must be changed also in a situation with initial aggressive treatment with maximal doses of drugs administered, or with maintaining therapy, when we try to prevent disease recurrence with long-term administration of lower doses. Biologic therapy is very promising for many patients, and antibodies against tumour necrosis factor alpha above all. Intensive clinical trials are running worldwide with other drugs of this group.

Download citation

References

  1. Crohn BB, Ginzburg L, Openheimer GD. Regional ileitis; a pathological and clinical entity. JAMA 1932; 99: 1323-1329. Go to original source...
  2. De Dombal FT, Burton I, Coligher JC. Recurrence of Crohn´s disease after primary excisional surgery. Lancet 1971; 12: 519-527. Go to original source...
  3. Kohout P, Pavlíčková J. Crohnova choroba, ulcerózní kolitida. Nakladatelství Pavla Momčilová, Čestlice 1998: 19-27.
  4. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977; 1: 892 - 895. Go to original source... Go to PubMed...
  5. Ishaq S, Green JR. Tolerability of aminosalicylates in inflammatory bowel disease. Bio Drugs 2001; 15: 339-49. Go to original source... Go to PubMed...
  6. Zbořil V. Kortikosteroidy v léčbě nespecifických střevních zánětů. Praha, Galén 2001: 26-33.
  7. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn´s disease. Gut 1994; 36: 360-362. Go to original source... Go to PubMed...
  8. Candy S, Wright J, Gerber M, et al. A controled double blind study of azathioprine in the managment of Crohn´s disease. Gut 1995; 37: 674-678. Go to original source... Go to PubMed...
  9. Sandborn WJ, Targan, SR. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002; 122: 1952-1608. Go to original source... Go to PubMed...
  10. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn´s disease: A user´s guide for clinicians. Am J Gastroenterol 2002; 97: 2962-2972. Go to original source... Go to PubMed...
  11. Fuller R, Gibson, GR. Modifications of the intestinal microflora using probiotics and prebiotics. Scand J Gastroenterol 1997; 222: 28-31. Go to original source... Go to PubMed...
  12. Lukáš M. Medikamentózní terapie idiopatických střevních zánětů. In: Lukáš M. Idiopatické střevní záněty, nejistoty, současné znalosti a klinický přístup. Praha, Galén 1998: 245-268.
  13. Rutgeerts P, Colombel J, Schreiber S, et al. Treatment of of Crohn´s disease: response to Remicade (infliximab) in the ACCENT I trial trough week 54. Am J Gastroenterol 2001; 96: 303. Go to original source...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.